Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia

Journal of Clinical Investigation

Volumn 106, Issue 5, 2000, Pages 705-714

  Wu, Catherine J ^a,c   Yang, Xiao Feng ^a,c   McLaughlin, Stephen ^a   Neuberg, Donna ^b   Canning, Christine ^a   Stein, Brady ^a   Alyea, Edwin P ^a,c   Soiffer, Robert J ^a,c   Dranoff, Glenn ^a,c   Ritz, Jerome ^a,b,c  

^a Center for Hematology   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; FOCAL ADHESION KINASE; GAMMA INTERFERON;

ANTIBODY TITER; ANTIGEN RECOGNITION; ARTICLE; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA LIBRARY; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; LYMPHOCYTE TRANSFUSION; PRIORITY JOURNAL; REMISSION; T LYMPHOCYTE;

EID: 0033813320     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI10196     Document Type: Article

References (58)

1. Gale, R.P., et al. 1998. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. Blood. 91:1810-1819.
2. van Rhee, F., et al. 1997. Long-term results after allogeneic bone marrow transplantation for chrome myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 20:553-560.
3. Gratwohl, A., et al. 1995. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Blood. 86:813-818.
4. Horowitz, M.M., et al. 1990. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 75:555-562.
5. Sehn, L.H., et al. 1999. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelagenous leukemia: impact of donor lymphocyte infusion. J. Clin. Oncol. 17:561-568.
6. Kolb, H.J., et al. 1995. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 86:2041-2050.
7. Porter, D., Roth, M., McGarigle, C., Ferrara, J., and Antin, J. 1994. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N. Engl. J. Med. 330:100-106.
8. Giralt, S., et al. 1995. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia arter allogeneic bone marrow transplantation. Blood. 86:4337-4343.
9. Alyea, E.P., et al. 1998. Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 91:3671-3680.
10. Dolstra, H., et al. 1999. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J. Exp. Med. 189:301-308.
11. Faber, L.M., et al. 1995. Recognition of clonogenic leukemia cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. J. Clin. Invest. 96:877-883.
12. den Haan, J.M.M., et al. 1998. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science. 279:1054-1057.
13. Perreault, C., Roy, D.C., and Fortin, C. 1998. Immunodominant minor histocompatibility antigens: the major ones. Immunol. Today. 19:69-74.
14. Warren, E.H., et al. 2000. The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. J. Immunol. 164:2807-2814.
15. Old, L. 1981. Cancer immunology: the search for specificity. Cancer Res. 41:361-375.
16. Dropcho, E., Chen, Y., Posner, J., and Old, L. 1987. Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration. Proc. Natl. Acad Sci. USA. 84:4552-4556.
17. Albert, M., et al. 1998. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat. Med. 4:1321-1324.
18. Sahin, U., et al. 1995. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA. 92:11810-11813.
19. Old, L.J., and Chen, Y.-T. 1998. New paths in human cancer serology. J. Exp. Med. 187:1163-1167.
20. Jager, E., et al. 2000. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc. Natl. Acad. Sci. USA. 97:4760-4765.
21. Ling, M., Wen, Y.-J., and Lim, S.H. 1998. Prevalence of antibodies against proteins derived from leukemia cells in patients with chronic myeloid leukemia. Blood. 92:4764-4770.
22. Soiffer, R.J., et al. 1992. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J. Clin. Oncol. 10:1191-1200.
23. Li, J., Avraham, H., Rogers, R., Raja, S., and Avraham, S. 1996. Characterization of RAFTK, a novel focal adhesion kinase, and its integrin-dependent phosphorylation and activation in megakaryocytes. Blood. 88:417-428.
24. Jager, E., et al. 1998. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187:265-270.
25. Sahin, U., Tureci, O., and Pfreundschuh, M. 1997. Serological identification of human tumor antigens. Curr. Opin. Immunol. 9:709-716.
26. Chen, Y., et al. 1997. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA. 94:1914-1918.
27. Brass, N., et al. 1999. Role of amplified genes in the production of autoantibodies. Blood. 93:2158-2166.
28. Wang, R.-F., Wang, X., and Rosenberg, S. 1999. Identification of a novel major histocompatibility complex class-II restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4+ T cells. J. Exp. Med. 189:1659-1667.
29. Yotnda, P., et al. 1998. Cytotoxic T cell response against the chimeric p210 bcr-abl protein in patients with chronic myelogenous leukemia. J. Clin. Invest. 101:2290-2296.
30. Pieper, R., et al. 1999. Biochemical identification of a mutated human melanoma antigen recognized by CD4+ T cells. J. Exp. Med. 189:757-765.
31. Wang, R.-F., Wang, X., Atwood, A.C., Topalian, S.L., and Rosenberg, S.A. 1999. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science. 284:1351-1354.
32. Bowne, W., et al. 1999. Coupling and uncoupling of tumor immunity and autoimmunity. J. Exp. Med. 190:1717-1722.
33. Cargill, M., et al. 1999. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat. Genet. 22:231-238.
34. Falkenburg, J., Smit, W., and Willemze, R. 1997. Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia. Immunol. Rev. 157:223-230.
35. Goulmy, E., et al. 1996. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N. Engl. J. Med. 334:281-285.
36. Warren, E.H., Greenberg, P.D., and Riddell, S.R. 1998. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood. 91:2197-2207.
37. Mutis, T., et al. 1999. Tetrameric MLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Natl. Med. 5:839-842.
38. Tseng, L.H., et al. 1999. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation. Blood. 94:2911-2914.
39. Avraham, S., et al. 1995. Identification and characterization of a novel related adhesion focal tyrosine kinase (RAFTK) from megakaryocytes and brain. J. Biol. Chem. 270:27742-27751.
40. Salgia, R., et al. 1996. The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells. J. Biol. Chem. 271:31222-31226.
41. Nieto, M., et al. 1999. Signaling through CD43 induces natural killer cell activation, chemokine release and Pyk2 activation. Blood. 94:2767-2777.
42. Liu, Z., et al. 1997. Cytokine signaling through the novel tyrosine kinase RAFTK in Kaposi's sarcoma cells. J. Clin. Invest. 99:1798-1804.
43. Chauhan, D., et al. 1999. RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells. Oncogene. 18:6733-6740.
44. Milner, L., and Bigas, A. 1999, Notch as a mediator of cell fate determination in hematopoiesis: evidence and speculation. Blood. 93:2431-2448.
45. Dou, S., et al. 1994. The recombination signal sequence-binding protein RBP-2N functions as a transcriptional repressor. Mol. Cell. Biol. 14:3310-3319.
46. Grossman, S., Johannsen, E., Tong, X., Yalamanchili, R., and Kieff, E. 1994. The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proc. Natl. Acad. Sci. USA. 16:7568-7572.
47. Henkel, T., Ling, P., Hayward, D., and Peterson, M. 1994. Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein Jκ. Science. 265:92-95.
48. Oswald, F., Liptay, S., Adler, G., and Schmid, R. 1998. NF-κB2 is a putative target gene of activated Notch-1 via RBP-Jκ. Mol. Cell. Biol. 18:2077-2088.
49. Plaisance, S., Vanden Berghe, W., Bonne, E., Fiers, W., and Haegeman, G. 1997. Recombination signal sequence binding protein Jkappa is constitutively bound to the NF-kappaB site of the interleukin-6 promoter and acts as a negative regulatory factor. Mol. Cell. Biol. 17:3733-3743.
50. Korganow, A.-S., et al. 1999. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity. 10:451-461.
51. Matsumoto, I., Staub, A., Benoist, C., and Mathis, D. 1999. Arthiritis provoked by linked T and B cell recognition of a glycolytif enzyme. Science. 286:1732-1735.
52. Madsen, P., et al. 1999. Psoriasis upregulated phorbolin-1 shares structural but not functional similarity to the mRNA-editing protein apobec-1. J. Invest. Dermatol. 113:162-169.
53. Woodage, T., Basrai, M.A., Baxevanis, A.D., Hieter, P., and Collins, F.S. 1997. Characterization of the CHD family of proteins. Proc. Natl. Acad. Sci. USA. 94:11472-11477.
54. Nagase, T., et al. 1998. Prediction of the coding sequences of unidentified human genes. IX. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro. DNA Res. 5:31-39.
55. Amakawa, R., et al. 1993. Human Jk recombination signal binding protein gene (IGKJRB): comparison with its mouse homologue. Genomics. 17:306-315.
56. Gondo, H., et al. 1987. Differential expression of the human thymosin beta-4 gene in lymphocytes, macrophages, and granulocytes. J. Immunol. 139:3840-3848.
57. Mars, W.M., van Tuinen, P., Drabkin, H.A., White, J.W., and Saunders, G.F. 1988. A myeloid-related sequence that localizes to human chromosome 8q21.1-22. Blood. 71:1713-1719.
58. Saijo, M., et al. 1995. Molecular cloning of a human protein that binds to the retinoblastoma protein and chromosomal mapping. Genomics. 27:511-519.